$ALVO News

Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026

Alvotech's Manufacturing Progress, Simponi Launch Potential Support Recovery, UBS Says

Alvotech shares jump premarket after FDA approves new Simlandi process

Alvotech Receives FDA Approval for New SIMLANDI® Manufacturing Process That More Than Doubles Output Per Batch

Alvotech Stock In Focus After Europe Filing For Eylea 8 Mg Copycat

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

LOTTE Biologics and Alvotech announce US-based manufacturing agreement to increase global supply

Alvotech (ALVO) Could Be 14% Undervalued On Manufacturing Capacity Updates

Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply

Alvotech And LOTTE Biologics Announce Long-Term Strategic Manufacturing Partnership For Biosimilar Products

Alvotech Soars 13% on FDA Nod That “Effectively Doubles” US Humira Biosimilar Capacity

Alvotech stock surges after FDA manufacturing approval

FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®

FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®

Alvotech Gets FDA Nod For Added US Manufacturing Capacity For Humira Biosimilar SIMLANDI, Doubling Drug Substance Capacity At Reykjavik Site

Why This Biotech Stock Just Got a Rare Double Upgrade

ALVO Stock Jumps On Double Upgrade — Why Barclays Sees A 59% Upside

Alvotech Shares Rise 5.6% After Barclays Upgrades Rating and Doubles Price Target

Barclays Upgrades Alvotech to Overweight, Raises Price Target to $8